# Genetic association studies of fibromuscular dysplasia identify new risk loci and shared genetic basis with more common vascular diseases

- 4
- 5

Adrien Georges<sup>1#</sup>, Min-Lee Yang<sup>2,3#</sup>, Takiy-Eddine Berrandou<sup>1#</sup>, Mark Bakker<sup>4</sup> Ozan 6 Dikilitas<sup>5</sup>, Soto Romuald Kiando,<sup>1</sup> Lijiang Ma<sup>6</sup>, Benjamin A. Satterfield<sup>5</sup>, Sebanti Sengupta<sup>2</sup>, 7 Mengyao Yu<sup>1</sup>, Jean-François Deleuze<sup>7</sup>, Delia Dupré<sup>1</sup>, Kristina L. Hunker<sup>2,3</sup>, Sergiy 8 Kyryachenko<sup>1</sup>, Lu Liu<sup>1</sup>, Laurence Amar<sup>1,8</sup>, Chad M. Brummett<sup>9</sup>, Dawn M. Coleman<sup>10</sup>, 9 Valentina d'Escamard<sup>11</sup>, Peter de Leeuw<sup>12,13</sup>, Natalia Fendrikova-Mahlay<sup>14</sup>, Daniella Kadian-10 Dodov<sup>15</sup>, Jun Z. Li<sup>3</sup>, Aurélien Lorthioir<sup>1,8</sup>, Marco Pappaccogli<sup>16,17</sup>, Aleksander Prejbisz<sup>18</sup>, 11 Witold Smigielski<sup>19</sup>, James C. Stanley<sup>10</sup>, Matthew Zawistowski<sup>20</sup>, Xiang Zhou<sup>20</sup>, Sebastian 12 Zoellner<sup>20</sup>, FEIRI investigators<sup>21</sup>, International stroke genetics consortium (ISGC) 13 intracranial aneurysm working group<sup>21</sup>, MEGASTROKE<sup>21</sup>, <sup>22</sup>, Marc L. De Buyzere<sup>23</sup>, 14 Stéphanie Debette<sup>24</sup>, Piotr Dobrowolski<sup>18</sup>, Wojciech Drygas<sup>25</sup>, Heather L. Gornik<sup>14</sup>, Jeffrey 15 W. Olin<sup>15</sup>, Jerzy Piwonski<sup>25</sup>, Ernst R. Rietzschel<sup>26</sup>, Ynte Ruigrok<sup>4</sup>, Miikka Vikkula<sup>27</sup>, Ewa 16 Warchol Celinska<sup>18</sup>, Andrzej Januszewicz<sup>18</sup>, Iftikhar J. Kullo<sup>5</sup>, Michel Azizi<sup>8,28</sup>, Xavier 17 Jeunemaitre<sup>1,29</sup>, Alexandre Persu<sup>16,30</sup>, Jason C. Kovacic<sup>6,31,32</sup>, Santhi K. Ganesh<sup>2,3&\*</sup>, Nabila 18 19 Bouatia-Naji<sup>1&\*</sup>

20

21 Affiliations

<sup>1.</sup> Université de Paris, INSERM, Paris Cardiovascular Research Center, F-75006 Paris,
 France

It is made available under a CC-BY-NC-ND 4.0 International license .

24	2.	Division of Cardiovascular Medicine, Department of Internal Medicine, University of
25		Michigan Medical School, Ann Arbor, MI, USA
26	3.	Department of Human Genetics, University of Michigan Medical School, Ann Arbor,
27		MI, USA
28	4.	Department of Neurology and Neurosurgery, University Medical Center Utrecht Brain
29		Center, Utrecht University, Utrecht, The Netherlands
30	5.	Department of Cardiovascular Medicine, Mayo Clinic, Rochester MN 55902 USA
31	6.	Icahn Institute for Genomics and Multiscale Biology, Icahn School of Medicine at
32		Mount Sinai, New York, NY, USA
33	7.	Centre National de Recherche en Génomique Humaine, Institut de Génomique, CEA
34		and Fondation Jean Dausset-CEPH, Evry, France
35	8.	Hypertension Unit, Assistance Publique-Hôpitaux de Paris, Hôpital Européen Georges
36		Pompidou, F-75015 Paris, France
37	9.	Department of Anesthesiology, Michigan Medicine, University of Michigan, Ann
38		Arbor, MI, USA
39	10.	Vascular Surgery Section, Department of Surgery, Michigan Medicine, University of
40		Michigan, Ann Arbor, MI, 48109, USA
41	11.	Cardiovascular Institute, Icahn School of Medicine at Mount Sinai, New York, NY,
42		USA
43	12.	Department of Internal Medicine, Division of General Internal Medicine, Section
44		Vascular Medicine, Maastricht University Medical Centre, Maastricht University,
45		Maastricht, the Netherlands
46	13.	CARIM School for Cardiovascular Diseases, Maastricht University Medical Centre,
47		Maastricht University, Maastricht, the Netherlands
48	14.	Heart and Vascular Institute, Cleveland Clinic, Cleveland, OH, 44195, USA

It is made available under a CC-BY-NC-ND 4.0 International license .

49	15.	Zena and Michael A. Wiener Cardiovascular Institute and Marie-Josée and Henry R.
50		Kravis Center for Cardiovascular Health Icahn School of Medicine at Mount Sinai.
51	16.	Division of Cardiology, Cliniques Universitaires Saint-Luc, Université Catholique de
52		Louvain, 1200 Brussels, Belgium
53	17.	Division of Internal Medicine and Hypertension Unit, Department of Medical
54		Sciences, University of Turin, Turin, Italy
55	18.	Department of Hypertension, National Institute of Cardiology, Warsaw, Poland
56	19.	Department of Demography, University of Lodz, Lodz, Poland
57	20.	Department of Biostatistics and Center for Statistical Genetics, University of
58		Michigan School of Public Health, Ann Arbor, MI, USA
59	21.	A full list of authors and their affiliations is provided in the supplementary material.
60	22.	Univ. Lille, Inserm, CHU Lille, Institut Pasteur de Lille, U1167 - RID-AGE - Labex
61		DISTALZ - Risk factors and molecular determinants of aging-related disease, F-
62		59000 Lille, France
63	23.	Department of Cardiovascular Diseases, Ghent University and Ghent University
64		Hospital, Ghent, Belgium
65	24.	Department of Neurology, Bordeaux University Hospital, Inserm U1219, Bordeaux,
66		France
67	25.	Department of Epidemiology, Cardiovascular Disease Prevention, and Health
68		Promotion, National Institute of Cardiology, Warsaw, Poland
69	26.	Department of Cardiovascular Diseases, Ghent University and Ghent University
70		Hospital, Ghent, Belgium
71	27.	Human Molecular Genetics, de Duve Institute, Université Catholique de Louvain,
72		1200 Brussels, Belgium

It is made available under a CC-BY-NC-ND 4.0 International license .

73	28.	Université de Paris, Inserm, Centre d'Investigation Clinique 1418, F-75006, Paris,
74		France
75	29.	Department of Genetics, Assistance-Publiques-Hôpitaux de Paris, Hôpital Européen
76		Georges Pompidou, F-75015 Paris France
77	30.	Pole of Cardiovascular Research, Institut de Recherche Expérimentale et Clinique,
78		Université Catholique de Louvain, 1200 Brussels, Belgium
79	31.	Victor Chang Cardiac Research Institute, Darlinghurst, Australia
80	32.	University of New South Wales, Sydney, Australia
81		<sup>#</sup> First authors
82		<sup>&amp;</sup> Last authors
83		* Corresponding authors.
84		

It is made available under a CC-BY-NC-ND 4.0 International license .

#### 86 ABSTRACT

87 Fibromuscular dysplasia (FMD) is an arteriopathy that presents clinically by hypertension and 88 stroke, mostly in early middle-aged women. We report results from the first genome-wide 89 association meta-analysis of FMD including 1962 FMD cases and 7100 controls. We 90 confirmed PHACTR1 and identified three new loci (LRP1, ATP2B1, and LIMA1) associated 91 with FMD. Transcriptome-wide association analysis in arteries identified one additional locus 92 (SLC24A3). FMD associated variants were located in arterial-specific enhancers active in 93 vascular smooth muscle cells and fibroblasts. Target genes are broadly involved in 94 mechanisms related to actin cytoskeleton and intracellular calcium homeostasis, central to 95 vascular contraction. Cross-trait linkage disequilibrium analyses identified positive genetic 96 correlations with blood pressure, migraine and intracranial aneurysm, and an inverse 97 correlation with coronary artery disease, independent from the genetics of blood pressure.

It is made available under a CC-BY-NC-ND 4.0 International license .

#### 99 Introduction

100 Cardiovascular disease (CVD) is the primary cause of mortality in the world. CVD causes 101  $\sim$ 18 million deaths each year, of which 85% are due to stroke and myocardial infarction 102  $(MI)^{1}$ . Renal artery stenosis is a cause of hypertension, a preventable risk factor for stroke and 103 MI. Renovascular hypertension results from numerous factors, which include atherosclerosis or fibromuscular dysplasia (FMD) in  $\sim 10\%$  of cases<sup>2</sup>. While atherosclerosis has been widely 104 105 studied and its genetic architecture has been well defined, little is known about the 106 pathogenesis or genetics of FMD. To date, only PHACTR1, a pleiotropic locus involved in 107 the genetic risk of several cardiovascular and neurovascular diseases, has been reported to be associated with FMD<sup>3</sup>. 108

109 FMD occurs predominantly in early middle-aged women (mean age at diagnosis 46-53 years)<sup>4</sup>, thus representing a subset of the population where cardiovascular and neurovascular 110 disease present differently depending on sex<sup>5,6</sup>. FMD is an idiopathic, segmental, non-111 112 atherosclerotic disease of the arterial walls, leading to stenosis of small and medium-sized arteries, often associated to dissection, aneurysm, and in some cases arterial tortuosity<sup>4,7-9</sup>. 113 114 The prevalence of FMD is hard to estimate due to the need of comprehensive vascular 115 imaging to make a definitive diagnosis while concurrently excluding the presence of 116 atherosclerotic plaques. Diagnosis is often made incidentally on imaging (-3-4%) in healthy kidney donors<sup>10</sup>), as part of an investigation to elucidate early onset and/or resistant 117 118 hypertension, following a stroke event or spontaneous coronary artery dissection, a form of acute myocardial infarction associated with female sex as well<sup>11</sup>. 119

120 Investigating the genetic basis of FMD has been a challenging endeavour due to two main 121 reasons: *i*) poor recognition from the general medical community of this underestimated cause 122 of arterial stenosis due to its atypical presentation in women with few cardiovascular risk 123 factors, who are theoretically considered as protected from CVD; *ii*) the effort needed to

It is made available under a CC-BY-NC-ND 4.0 International license .

124 collect large cohorts of patients where adequate imaging through computed tomographic 125 angiography or magnetic resonance angiography was conducted to precisely define the non-

126 atherosclerotic phenotype and provide sufficient power to conduct genetic studies<sup>4</sup>.

127 Here we report findings from a meta-analysis of six genome-wide association studies 128 (GWAS) from Europe and the United States of America to investigate the genetic basis of 129 FMD in 1962 patients and 7100 controls. We conducted a single nucleotide polymorphism 130 (SNP)-level GWAS, gene-based GWAS, and transcriptome-wide association study (TWAS) 131 in arteries. We confirmed the previously associated locus *PHACTR1* and identified three 132 novel risk loci associated with FMD at the SNP level and several novel genes associated to 133 FMD at the gene or transcriptome level. Through the integration of annotation datasets 134 generated in fibroblasts, smooth muscle and endothelial cells, combined with public resources 135 available in arteries, we prioritized variants and identified target genes in most loci. We found 136 that risk genes for FMD are specifically and consistently expressed in smooth muscle cells, 137 fibroblasts and arterial tissue and are involved in regulatory mechanisms related to actin 138 cytoskeleton and intracellular calcium homeostasis, a mechanism central to vascular 139 contraction. Using linkage disequilibrium score regression, we found an important genetic 140 overlap between FMD and blood pressure, migraine, intracranial aneurysm, coronary artery 141 disease and MI, and demonstrated that genetics of blood pressure is not driving the genetic 142 association or correlation with FMD.

It is made available under a CC-BY-NC-ND 4.0 International license .

#### 144 **RESULTS**

145

#### 146 Meta-analysis of six genome-wide association studies revealed new risk loci for FMD

147 We tested ~6.5 million common genetic variants (MAF>0.01) in 1962 FMD cases and 7100 148 controls. All studies involved participants of European ancestry and were adjusted for sex, the 149 first five principal components and individual study genomic control. Three loci contained 150 SNPs associated with FMD at the genome-wide significance level (Supplementary Figure 151 **S1, Table 1, Figure 1a)**; the previously identified *PHACTR1* locus on chromosome 6 (lead SNP rs9349379, OR=1.39, 95%CI: 1.28-1.51,  $P = 2.0 \times 10^{-14}$ ), *LRP1* on chromosome 12 152 (rs11172113, OR=1.31, 95%CI: 1.20-1.43,  $P = 2.6 \times 10^{-10}$ ) and rs17249754, located 10kb 153 154 downstream of ATP2B1 on chromosome 12 as well (OR=1.41, 95%CI: 1.26-1.58, P = $5.9 \times 10^{-9}$ ). A GWAS restricted to multifocal FMD, which is characterized by multiple stenoses 155 156 and is the major FMD subtype (91%, Supplementary Table S1), identified one additional signal in *LIMA1* on chromosome 12 (rs6580732, OR=1.30, 95%CI: 1.19-.41,  $P = 2.2 \times 10^{-9}$ , 157 158 Figure 1a, Supplementary Figure S1, Table 1). Despite mapping to the same chromosome, 159 LIMA1, LRP1 and ATP2B1 loci are fully independent and map on positions 50.5, 57.5 and 160 90.1 megabases on chromosome 12, respectively. A GWAS in women only cases (87% of 161 patients) identified the same four loci as significantly associated with FMD, with comparable 162 effect sizes and levels of significance (Supplementary Figure S1, Table 1, Supplementary 163 Tables S2-S4). Given the small sample size (N=247), a GWAS in men only was not 164 conducted.

165

#### 166 FMD associated variants regulate the expression of nearby genes in arterial tissues

167 To identify potential target genes at FMD associated loci, we queried the GTEx database for 168 eQTL association of lead variants in all tissues available (v8 release, **Figure 2a**)<sup>12</sup>.

It is made available under a CC-BY-NC-ND 4.0 International license .

169 Interestingly, the lead SNPs in all four loci were identified among top eQTLs of at least one

170 nearby gene in one or more of the three available arterial tissues (Figure 2a).

171 At the PHACTR1 locus, FMD risk allele (rs9349379-A) was associated with increased 172 *PHACTR1* expression in all arterial tissues analysed ( $P_{Arterv-Tibial}=8.0\times10^{-42}$ , Figure 2b,  $P_{Arterv$  $_{Aorta}=2.0\times10^{-17}$ ,  $P_{Artery-Coronary}=3.0\times10^{-9}$ ). Colocalization analyses between eQTLs in arterial 173 174 tissues and FMD association strongly supported rs9349379 to be the causative variant on this 175 locus (posterior probability 99.2%, Figure 2c). PHACTR1 encodes a member of the 176 phosphatase and actin regulator family of proteins implicated in the reorganisation of actin 177 cytoskeleton and tubule formation. Interestingly, rs9349379-PHACTR1 expression correlation 178 was also found in primary dermal fibroblasts cell lines from FMD patients (N=83) and 179 matched controls (N=70). This finding was observed when all samples were jointly analysed 180 (P = 0.01), in the FMD group only (P = 0.01), but not in the control group (Supplementary 181 Figure S2).

182 At the LRP1 locus, rs11172113 was highly correlated with LRP1 expression in tibial arteries  $(P_{Arterv-Tibial}=9.4\times10^{-21},$  Figure 2d), aorta  $(P_{Arterv-Aorta}=3.6\times10^{-15})$  and to a lesser extent 183 coronary artery tissues ( $P_{Artery-Coronary}=2.4\times10^{-4}$ ). The FMD risk allele (rs11172113-T) was 184 185 associated with increased expression of LRP1 and rs11172113 was also supported by the 186 colocalization analysis as the most likely causal variant at this locus (Posterior probability 187 99.2%, Figure 2e) LRP1 encodes low density lipoprotein receptor related protein 1, a 188 scavenger receptor involved in numerous cellular processes including intracellular signalling. 189 As for the ATP2B1 locus, the strongest eQTL association involving rs17249754 in artery tissue was with ATP2B1 in tibial arteries ( $P_{Artery-Tibial}=1.5\times10^{-17}$ , Figure 2f) and aorta samples 190 191  $(P_{Arterv-Aorta}=5.1\times10^{-5})$ , whereas no association was detected in coronary arteries. The FMD

- 192 risk allele (rs17249754-G) was associated with decreased expression of *ATP2B1* in arterial
- 193 tissues (Figure 2f). Colocalization analysis of FMD association and expression in arterial

It is made available under a CC-BY-NC-ND 4.0 International license .

194 tissue supports a common causal variant (posterior probability 85.5%, Figure 2g). We note 195 that the ATP2B1 antisense transcript (ATP2B1-AS) was also predicted as potentially regulated by the same causal variant (posterior probability 76.6%, Supplementary Figure S3a). 196 ATP2B1 encodes the ATPase plasma membrane  $Ca^{2+}$  transporting 1 involved in intracellular 197 198 calcium homeostasis. 199 Several eQTL signals were found at the *LIMA1* locus, but none colocalized clearly with the 200 FMD association signal (Figure 2i, Supplementary Figure S3b-d). ATF1 was the strongest 201 eQTL protein-coding gene in arterial tissues ( $P_{Arterv-Aorta}=1.4\times10^{-14}$ , Figure 2h,  $P_{Arterv-Aorta}=1.4\times10^{-14}$ ,

202  $_{Tibial}$ =8.9×10<sup>-13</sup>,  $P_{Artery-Coronary}$ =1.7×10<sup>-3</sup>), with FMD risk allele (rs6580732-T) being associated 203 with lower expression of *ATF1* (**Figure 2h**). However, colocalization analysis of these two 204 signals was inconclusive (posterior probability = 0.6%, **Figure 2i**). *LIMA1* encodes LIM 205 domain and actin binding 1 involved in actin filament depolymerisation while *ATF1* is the 206 gene encoding activating transcription factor 1, an activating transcription factor involved in 207 cell growth and survival.

208

#### 209 Gene-based association and transcriptome-wide association studies identify additional

210 FMD associated genes

211 GWAS efficiently captures the effect of single variants affecting traits or diseases but may not 212 detect the combined effect of multiple variants independently affecting disease outcome and 213 located in the same gene. To address this limitation in our genetic investigation, we performed gene-based association analyses using MAGMA<sup>13</sup>, a regression-based gene and 214 gene-set analyses for GWAS data implemented in FUMA<sup>14</sup>. We identified four genes, all on 215 216 chromosome 12 from two different loci to be associated with FMD in at least one of the tested 217 conditions (all FMD cases, multifocal FMD, women only, Bonferroni corrected P < 0.05, 218 Figure 1b, Table 2). These included three genes at the *LIMA1* locus (*LIMA1*, *P*<sub>Women</sub>=3.0×10<sup>-</sup>

It is made available under a CC-BY-NC-ND 4.0 International license .

219 <sup>7</sup>, ATF1, 
$$P_{Multifocal}=7.3\times10^{-7}$$
 and GPD1,  $P_{Multifocal}=7.3\times10^{-7}$ ) and STAT6, located near LRP1

220 
$$(P_{Multifocal}=2.4\times10^{-6}).$$

221 To get a global view of the potential transcriptional effects of FMD associated variants in arteries, we conducted a TWAS using the FUSION software<sup>15</sup>, and gene expression models 222 223 calculated from tibial artery eQTL analysis from GTEx (v7 release). In line with FMD 224 association and eQTLs analyses, we found a significant association between genetically predicted expression levels of *PHACTR1* ( $P = 1.1 \times 10^{-11}$ ), *LRP1* ( $P = 2.7 \times 10^{-10}$ ) and *ATP2B1* 225  $(P = 3.7 \times 10^{-6})$  in arterial tissue and FMD (Table 2, Figure 1c-d, Supplementary Table S4). 226 227 No gene in the *LIMA1* locus was identified as a TWAS hit, although genetically predicted expression of ATF1 and LIMA1 were suggestively associated with FMD ( $P_{ATF1} = 2 \times 10^{-3}$ , 228  $P_{LIMAI} = 7 \times 10^{-3}$ , **Table 2**). 229

230 In addition to genes located in close proximity of genome-wide FMD-associated loci, we 231 found SLC24A3 (chromosome 20) to be a robust TWAS hit in tibial artery samples (P = $5.1 \times 10^{-9}$ . Figure 1c-d). Of note, *SLC24A3* was also a suggestive hit in the gene-based 232 233 association study ( $P_{All}=4.5\times10^{-6}$ ) (**Table 2**). SLC24A3 overlaps two independent and suggestive FMD association signals (lead SNP: rs2424245,  $P = 4.0 \times 10^{-7}$ , secondary SNP: 234 rs6046121,  $P = 1.2 \times 10^{-5}$ , correlation r<sup>2</sup><0.01, Supplementary Figure S4). FMD risk alleles 235 236 of both variants associated with lower SLC24A3 expression in artery tissue (rs6046121-A:  $P_{Tibial artery} = 2.0 \times 10^{-11}, P_{Aorta} = 5.6 \times 10^{-6}; rs 2424245 - T: P_{Tibial artery} = 1.6 \times 10^{-4}, Supplementary$ 237 238 Figure S4). Similar to ATP2B1, SLC24A3 encodes a plasma membrane calcium exchanger also involved in intracellular calcium homeostasis. Results obtained from TWAS using 239 240 multifocal FMD and women FMD are reported in **Supplementary Figure S5** with overall 241 comparable findings to the whole sample findings.

242

It is made available under a CC-BY-NC-ND 4.0 International license .

#### **FMD** associated genes are expressed in vascular smooth muscle cells and fibroblasts

245 We looked-up the expression of FMD associated genes (**Table 2**) in publicly available mouse aorta single cell RNA-Seq data<sup>16</sup>, 665 tibial artery RNA-Seq samples from GTEx and 153 246 247 primary dermal fibroblasts cell lines derived from FMD patients (N = 83) and matched 248 controls (N = 70). Mouse a rta single cell experiment shows that *Phactr1*, Lrp1, Atp2b1, Atf1, 249 Lima1, Slc24a3 and Stat6 were mostly detected in vascular smooth muscle cells (VSMC) and 250 *Phactr1*, *Lrp1*, *Atp2b1*, *Atf1*, *Lima1* and *Stat6* in fibroblasts clusters, whereas only *Atp2b1* and 251 *Lima1* showed strong presence in endothelial cells (EC) clusters (Supplementary Figure 252 **S6**). 253 On the other hand, expressions of all the FMD-associated genes were detected in human tibial 254 artery samples from GTEx, although GPD1 had very low and variable expression levels 255 compared to the other genes (Supplementary Figure S7). Interestingly, SLC24A3 was less expressed in arterial samples of women ( $P = 1.1 \times 10^{-5}$ , Supplementary Figure S8), consistent 256 257 with its predicted decreased expression in FMD risk allele carriers. A trend toward higher

Figure S8), also these were consistent with the direction of effect of the FMD increasing risk alleles for *PHACTR1* but not for *ATF1*. However, we did not observe any differences in the expression of top FMD associated genes between fibroblasts samples derived from an all women group of FMD patients and those from sex-matched controls (**Supplementary Figure** S9).

expression in women was observed for *PHACTR1* and *ATF1* (P = 0.013, Supplementary

264

258

# FMD associated variants are located in regulatory elements active in arterial tissue and VSMCs

The FMD associated variants identified in this study are all located in non-coding regions, either intronic or intergenic. To obtain insights into their potential regulatory function, we

It is made available under a CC-BY-NC-ND 4.0 International license .

269 generated open chromatin profiles in human carotid artery-derived primary cells (two VSMC 270 and two EC primary cell lines), human coronary artery derived cells (one VSMC and one EC 271 primary cell line), human dermal (two cell lines) and cardiac fibroblasts (one cell line) using 272 ATAC-Seq. We also reanalysed existing data obtained using ATAC-Seq on healthy coronary 273 arteries<sup>17</sup>. Using a common pipeline analysis, we obtained 177,015 to 196,272 peaks from 274 cultured human VSMCs, 120,577 to 137,779 from ECs and fibroblasts, and 54,622 to 70,855 275 peaks from human coronary arteries (Figure 3a). Global correlation and principal component 276 analyses showed that open chromatin regions of fibroblasts and VSMCs are closely related, 277 whereas ECs and artery samples form separate clusters (Figure 3b-c). 278 Using the GREGOR algorithm<sup>18</sup>, we found that FMD-associated variants were enriched 279 among open chromatin peaks in artery tissue samples (average 1.6-fold enrichment, *P*-values:  $9 \times 10^{-5}$ - $1 \times 10^{-2}$ ), but not in VSMCs, ECs, or fibroblasts (Figure 3d). We found that, globally, 280 281 artery-specific ATAC-Seq peaks are overrepresented in the vicinity of genes involved in 282 contractile fibres and muscle system processes (Figure 3e-f). 283 Next, we annotated FMD associated variants with overlapping open chromatin regions we 284 generated in cells and re-analysed in coronary arteries, in addition to histone marks in artery 285 tissue previously generated through the ENCODE project. We defined as potentially causal 286 all variants that overlapped open chromatin peaks in at least one of the above-mentioned 287 arterial tissues or cell types (Table 3). Our analyses identified to at least one causal variant 288 per locus. At the *PHACTR1* locus on chromosome 6, the lead variant (rs9349379) belonged to 289 a chromatin region open in arterial tissue but not accessible in VSMCs, fibroblasts or ECs. 290 This variant also overlapped with well-defined enhancer marks in arterial tissue and is 291 strongly supported as the causal variant in this locus (Figure 4a-b). 292 The lead variant rs11172113 in *LRP1* overlapped with open chromatin peaks in arterial tissue,

293

primary VSMCs and fibroblasts, but not primary ECs (Figure 4c-d). Strong enhancer and

It is made available under a CC-BY-NC-ND 4.0 International license .

promoter marks were also present in arterial tissue in this region, which mapped 5kbdownstream of *LRP1* promoter.

296 The ATP2B1 locus included three highly associated variants (rs11105352, rs11105353 and 297 rs11105354, Figure 4e), which all overlapped a small open-chromatin peak specifically 298 observed in arterial tissue, and an enhancer-specific H3K4me1 histone mark (Figure 4f). Of 299 note, a suggestively associated SNP (rs73437382,  $P = 2.9 \times 10^{-6}$ ), in moderate LD ( $r^2 = 0.5$ ) 300 with rs11105354 was located in the promoter sequence of ATP2B1 and ATP2B1-AS1 and is 301 thus candidate for causality (**Figure 4e**). 302 Finally, in the FMD multifocal specific locus *LIMA1*, there were ~100 tightly correlated 303 variants spanning over 500kb (Figure 4g), but only three genome-wide significant variants

intronic to *LIMA1* overlapped open chromatin regions (**Figure 4h, Table 3**). rs7301566 overlaps a region active in arteries, VSMCs and fibroblasts and strong enhancer marks in arteries (**Figure 4h**). rs1109726, a suggestively associated variant, shows several marks of regulatory function and maps to the promoter of *ATF1*, ~480kb downstream of *LIMA1* (**Figure 4h**).

309

# FMD loci are associated with blood pressure traits but hypertension did not drive genetic association with FMD

FMD diagnosis is often made through radiographic imaging to investigate vascular anomalies in the context of pre-existing and unexplained hypertension, following a stroke event such as due to cervical artery dissection or following MI due to spontaneous coronary artery dissection. To investigate the potentially shared genetic basis of these clinical associations, we curated previously published GWAS on diseases of interest, mainly from GWAS catalog and the UK Biobank summary statistics database (http://www.nealelab.is/uk-biobank). We

It is made available under a CC-BY-NC-ND 4.0 International license .

restricted our curation to FMD lead variants and their proxies ( $r^2 \ge 0.5$ , Europeans from 1000

Genomes phase 3).

Strikingly, all FMD loci were previously associated with at least one trait related to blood pressure, with the same alleles being associated with increased FMD risk and higher blood pressure/hypertension risk (**Figure 5a**). FMD loci were all associated ( $P \le 5 \times 10^{-8}$ ) with pulse pressure and at least suggestively ( $P \le 1 \times 10^{-5}$ ) associated with hypertension, systolic blood pressure and diastolic blood pressure. The lead variants in *SLC24A3* that we identified in the gene-based association and TWAS were associated with blood pressure traits as well (**Figure 5a**).

327 Hypertension is reported in a large proportion of patients with FMD in general, and in the 328 majority of FMD cases in this study (51 to 80% of FMD cases, Supplementary Table S1). 329 To test for hypertension as a potential confounder driving the observed association signals, 330 we conducted both stratified and adjusted analyses for hypertension status for the GWAS lead 331 variants in the two largest cohorts of our meta-analysis: the French and the UM case control 332 studies (Supplementary Table S6). Adjustment for hypertension status marginally modified 333 the effects sizes and level of significance of the associations with FMD at all four loci, 334 including when the association was absent (*LIMA1* in the French study). Given the large 335 proportion of hypertension both in the cases and the controls of the French study, associations 336 with FMD were only observed in the larger stratum of hypertensive patients. However, all 337 four loci showed significant association with FMD both in hypertensive and non-hypertensive 338 individuals in the UM case control study, supporting that these loci impact FMD risk 339 independent of hypertension status in the FMD cases. Concordantly, in the meta-analysis 340 including all 6 individual studies, FMD associations at the top loci remained significant after 341 conditioning FMD association on the genetic association with systolic blood pressure

It is made available under a CC-BY-NC-ND 4.0 International license .

342 obtained from the recent, large-scale blood pressure GWAS meta-analysis<sup>19</sup> (**Supplementary** 

343 **Table S7**).

344

#### 345 FMD associated loci have pleiotropic associations with multiple vascular diseases

346 In addition to blood pressure, we investigated additional associations of the FMD-associated 347 loci and genes with several vascular diseases (Figure 5a). PHACTR1, LRP1 and SLC24A3 348 have been previously associated with migraine, with the same alleles at risk for FMD and 349 migraine. *PHACTR1* and *LRP1* were both involved in a wide range of vascular diseases, 350 including cervical artery dissection and spontaneous coronary artery dissection, in addition to 351 abdominal aortic aneurysm for LRP1. PHACTR1 and ATP2B1 were associated with coronary 352 artery disease (CAD) and MI, while LRP1 was suggestively associated to CAD, and in all 353 three loci the risk alleles were the opposite of those associated with FMD. Colocalization of 354 FMD association signals with the most relevant traits, in addition to the comparison of FMD 355 TWAS in tibial arteries with the other diseases (Figure 5b), suggested that the same variants 356 cause the associations with FMD, cervical artery dissection, migraine and CAD 357 (Supplementary Figure S10).

358

#### 359 Genetic relationships between FMD, cardiovascular and neurovascular diseases

In light of the important number of diseases where FMD loci and genes are involved, we used LD score regression<sup>20</sup> to calculate the genome-wide correlation between FMD and blood pressure traits, CAD and MI, migraine, several stroke sub-types, lipids and clinical traits related to renal function (**Figure 6a-b, Supplementary Table S8**). FMD was positively correlated with hypertension ( $r_g = 0.37$ ,  $P = 4 \times 10^{-8}$ ), systolic blood pressure ( $r_g = 0.44$ , P = $5 \times 10^{-10}$ ), diastolic blood pressure ( $r_g = 0.39$ ,  $P = 2 \times 10^{-9}$ ) and pulse pressure ( $r_g = 0.36$ , P = $1 \times 10^{-8}$ ). FMD also correlated positively with migraine ( $r_g = 0.37$ ,  $P = 2 \times 10^{-4}$ ), intracranial

It is made available under a CC-BY-NC-ND 4.0 International license .

aneurysm (pooled ruptured and unruptured,  $r_g = 0.34$ ,  $P = 7 \times 10^{-6}$ ), aneurysmal subarachnoid 367 haemorrhage ( $r_g = 0.37$ ,  $P = 4 \times 10^{-5}$ ), and cervical artery dissection, although this latter did not 368 survive correction for multiple testing ( $r_g = 0.78$ ,  $P = 1 \times 10^{-2}$ ). FMD was not genetically 369 370 correlated with several stroke subtypes, CAD and MI. We also found a negative genetic correlation between FMD and low-density lipoprotein cholesterol levels ( $r_g = -0.19$ ,  $P = 1 \times 10^{-10}$ 371 372 <sup>3</sup>). No significant correlation with any of the kidney function related traits was observed 373 (Figure 6b, Supplementary Table S8). Interestingly, genetic correlations after conditioning 374 the FMD associations results on genome-wide genetic associations with systolic blood pressure revealed a significant negative genetic correlation with CAD ( $r_g = -0.29$ ,  $P = 6 \times 10^{-5}$ ) 375 and MI ( $r_g = -0.28$ ,  $P = 2 \times 10^{-3}$ ) (Figure 6c, Supplementary Table S9), indicating that this 376 377 opposite genetic relation between FMD and CAD/MI is not mediated by common loci 378 between FMD and systolic blood pressure. FMD genetic correlation with migraine was only marginally affected by conditioning on systolic blood pressure genetics ( $r_g = 0.38$ ,  $P = 8 \times 10^{-10}$ 379 380 <sup>5</sup>). On the other hand, the genetic correlations with intracranial aneurysm, subarachnoid 381 haemorrhage and low-density lipoprotein cholesterol levels were less significant after 382 conditioning on systolic blood pressure genetics, indicating that these correlations with FMD 383 are in part due to the common genetic associated loci between FMD and systolic blood 384 pressure (Figure 6c-d, Supplementary Table S9). The correlation results were comparable 385 when we conducted the analyses after removing the top FMD associated loci 386 (Supplementary Tables S10 and S11).

It is made available under a CC-BY-NC-ND 4.0 International license .

#### 388 **DISCUSSION**

389 Our study is the most comprehensive genetic investigation dedicated to FMD, a non-390 atherosclerotic arterial disease primarily afflicting middle-aged women with few classical 391 cardiovascular risk factors. Key findings from our study include: i) Single SNP GWAS, gene-392 based GWAS and TWAS analyses in arteries identified three novel risk loci for FMD and 393 involved novel genes while confirming *PHACTR1*, the only known risk locus for FMD. *ii*) 394 Through integration of annotation datasets generated inhouse, combined with public 395 resources, we provided detailed prioritization of FMD risk variants and genes. We found that 396 FMD risk genes are consistently and specifically expressed in VSMCs, fibroblasts and arterial 397 tissue and are involved in regulatory mechanisms related to actin cytoskeleton and 398 intracellular calcium homeostasis, a mechanism central to vascular contraction. *iii*) We found 399 an important genetic overlap between FMD and blood pressure, not only for the associated 400 loci and genes but also globally at the GWAS level, but demonstrated that hypertension is not 401 driving the genetic association with FMD. iv) We reported shared genetic bases and 402 potentially biological mechanisms with some but not all cardiovascular and neurovascular 403 diseases, which is only partially driven by shared genetic basis with blood pressure.

The genetic investigation of FMD has been inconclusive for decades due to the lack of a clear genetic model. Efforts to establish large cohorts of FMD patients to conduct well-powered genetic studies are very recent and follow the increased awareness about its relatively high prevalence (~3%) in asymptomatic individuals<sup>21</sup>. FMD patients are commonly middle-aged women, long considered at low risk for the common cardiovascular diseases.

409 Our strategy combining single SNP and gene-based GWAS and TWAS in arterial tissues 410 identified three novel loci and several novel genes to contribute to FMD genetic risk. Most of 411 these loci were previously shown to be involved in multiple vascular diseases. *LRP1* is a risk

It is made available under a CC-BY-NC-ND 4.0 International license .

locus for pulse pressure<sup>22</sup>, migraine<sup>23</sup>, aortic abdominal aneurysm<sup>24</sup>, and was recently reported 412 for spontaneous coronary artery dissection<sup>25,26</sup> involving the same risk allele for FMD that 413 414 correlates with higher gene expression. However, the opposite allele was reported to increase the risk for MoyaMoya disease<sup>27</sup> and suggestively for CAD<sup>28</sup>. LRP1 plays important roles in 415 416 multiple cellular processes relevant to FMD such as the remodelling of the extracellular 417 matrix and VSMCs migration<sup>29</sup>. LRP1 function in VSMCs is mediated partly by the 418 modulation of calcium signalling, leading to deficient vasoconstriction in VSMC-specific 419 Lrp1-deficient mice<sup>30</sup>.

420 Interestingly, two of the genes we identified are directly involved in intracellular calcium 421 homeostasis, a highly relevant molecular mechanism to vascular contractility and 422 vasodilation. ATP2B1 encodes an ATP-dependent calcium channel specialized in the 423 exportation of calcium ions from the cytoplasm to the extracellular space. ATP2B1 is a well-424 established hypertension and blood pressure locus, where the same alleles increase the risk for 425 FMD and hypertension (Figure 4). Mice lacking Atp2b1 specifically in VSMCs exhibit 426 hypertension, higher intracellular calcium levels and increased sensitivity to nicardipine, a 427 calcium channel blocker<sup>31,32</sup>. On the other hand, *SLC24A3*, which we identified through the 428 TWAS analyses in tibial arteries to associate with FMD, encodes a transmembrane sodium/potassium/calcium exchanger also involved in calcium homeostasis<sup>33</sup>. The relevance 429 430 of impaired vasodilation and/or enhanced vasoconstriction in FMD pathogenesis is supported 431 by our recent study where we reported an enrichment among FMD patients for rare loss-of-432 function mutations in the gene encoding the receptor for prostacyclin, a major vasodilator 433 hormone<sup>34</sup>. In line with these findings, impaired dilation of arteries in response to sublingual 434 glyceryl trinitrate, a proxy for VSMC dysfunction, was reported in FMD patients, including in arterial segments clinically unaffected by the disease<sup>35</sup>. 435

436 The role of some novel genes in the pathogenesis of FMD is still unclear. The signal 437 transducer and activator of transcription 6 gene (STAT6) is a ubiquitous transcription factor 438 involved in intracellular processes linked to inflammation, although colocalization and eQTL 439 analyses privileged LRP1 as causal in this locus. GPD1 encodes a glycerol-3 phosphate 440 dehydrogenase 1 involved in lipid metabolism, which expression is detected at low levels in 441 arteries. In this locus, where effect estimates of associated variants were higher in multifocal 442 FMD and women, LIMA1 and ATF1 are two strong biological candidates. LIMA1 role in 443 actin dynamics is compatible with a potential role in maintaining cell shape, a feature lost in FMD affected VSMCs<sup>36</sup>. A study described a rare frameshift variant in *LIMA1* from a family 444 445 with inherited low LDL cholesterol and resistance in diet induced hypercholesterolemia in *Lima1* deficient mouse<sup>37</sup>. While its specific role in arteries is not known, ATF1 is a 446 447 transcriptional effector of the cyclic adenosine monophosphate pathway, which plays a key role in the regulation of vascular tone $^{38}$ . 448

449 Our study provides robust confirmation of the association with FMD of PHACTR1, a 450 pleiotropic locus that is involved in a large number of vascular diseases<sup>39,40</sup>. The functional 451 annotation using open chromatin in vascular cells and arterial tissue, the colocalization 452 analyses, TWAS in arteries and eQTL results, including specifically in FMD patients, all 453 point to rs9349379 as a clear regulator of *PHACTR1*, the most likely causal gene in FMD, and 454 probably in the other vascular diseases as well. The previously suggested regulation of the endothelin-1 gene  $(EDNI)^{39}$  is not supported by our results, or those from consequent works 455 that used an identical approach of iPSC induced endothelial cells<sup>41</sup> or measured endothelin-1 456 plasma levels in FMD patients and matched healthy controls<sup>42</sup>. On the other hand, the 457 458 phosphatase and actin-binding protein encoded by PHACTR1 regulates actin stress fibre assembly and cell motility<sup>43</sup>, functions highly relevant to the cellular disorganization that 459 characterizes VSMCs in multifocal FMD affected arteries<sup>36</sup>. Further investigation, especially 460

It is made available under a CC-BY-NC-ND 4.0 International license .

461 with *in vivo* models, are needed to more precisely define the function of *PHACTR1* in the

462 context of the genetic risk to a diverse panel of cardiovascular and neurovascular diseases.

463 Through genetic correlation analyses we were able to globally position the genetic basis of 464 FMD among the genetics of more commonly studied cardiovascular and neurovascular 465 diseases and traits. We showed that FMD shares a significant proportion of its genetic basis 466 with hypertension and blood pressure related traits, not only for the top associated loci and 467 genes but also genome-wide. FMD is often diagnosed in the context of hypertension, although 468 we have demonstrated that hypertension is not driving the genetic association with FMD in 469 the currently studied cohorts. Blood pressure regulation is highly complex and involves 470 multiple organs<sup>44</sup>. The identification of several genes related to intracellular calcium 471 regulation, and the absence of genetic correlation between FMD and multiple renal function 472 traits, suggests that impaired regulation of vascular tone genetically drives the multiple 473 stenoses phenotype observed in FMD that results in increased blood pressure. Future 474 exploration of more common genetic loci between FMD and blood pressure will certainly 475 enlighten additional mechanisms and potentially point to specific therapeutic targets to be 476 privileged in FMD hypertensive patients.

477 We showed an expected positive genetic correlation between FMD and migraine, which is reported by 25 to 69% of FMD patients<sup>4,8</sup>, and cervical artery dissection, which occurs in the 478 479 same cerebrovascular beds affected in FMD (i.e. carotid and vertebral arteries). However, we 480 found little support for shared genetics with ischemic stroke subtypes despite FMD being 481 frequently diagnosed in the context of a stroke event. On the other hand, FMD seems to be 482 more genetically related to intracranial aneurysm and aneurysmal subarachnoid haemorrhage. 483 This type of stroke shares several clinical characteristics with FMD, mainly high proportion 484 of patients < 55 years, association with blood pressure and smoking, and a higher propensity of women among patients<sup>45</sup>. Finally, we observed an inverse association between FMD and 485

It is made available under a CC-BY-NC-ND 4.0 International license .

486 CAD/MI both for the top loci and genes, and globally when FMD association is conditioned 487 on systolic blood pressure. The elimination of the presence of atherosclerosis as the cause of 488 stenoses and aneurysms is required for FMD diagnosis, which may have influenced this 489 negative correlation with a disease where atherosclerosis is under-represented. FMD is a 490 disease afflicting young to middle-aged women, who are less prone to develop CAD and MI, 491 which predominantly afflict older men. Whether FMD patients are less likely to develop 492 CAD/MI later in life, compared to patients of similar clinical characteristics is not known. 493 Endogenous or exogenous female hormones are considered to be protective factors from CAD/MI<sup>46</sup>, but are suspected as a potential risk factor in FMD pathogenesis, given the high 494 495 proportion of women among patients (80 to 90%) and the age of diagnosis of FMD (on 496 average  $\sim 50$  years)<sup>4</sup>. Oestrogens stimulate the release of vasodilator mediators such as nitric oxide and prostacyclin and inhibit the potent vasoconstrictor endothelin-1<sup>46</sup>. Our study did not 497 498 point to any direct link with sex hormone metabolism or regulation, except sex differences in 499 the level of expressions among women compared to men for PHACTR1 and SLC24A3. 500 consistent with the direction of effects of FMD risk alleles. More knowledge about detailed 501 biological and physiological roles of both genes are needed to address potential consequences 502 on artery remodelling in sex and atherosclerosis dependent contexts.

503

In summary, in this first meta-analysis of GWAS for FMD, we report robustly associated loci and genes and provide several new leads toward understanding biological mechanisms of stenosis and dissection in young women in the absence of atherosclerosis. Further investigation of the exact biological effects driven by these genes may shed light on the cause of higher prevalence of FMD in women and provide insights into the shared genetic basis between FMD and more common cardiovascular and neurovascular diseases.

It is made available under a CC-BY-NC-ND 4.0 International license .

#### 510 **REFERENCES**

- 512 1. World Health, O. *World health statistics 2020: monitoring health for the SDGs,* 513 *sustainable development goals,* (World Health Organization, Geneva, 2020).
- 514 2. Plouin, P.F. et al. Fibromuscular dysplasia. Orphanet J Rare Dis 2, 28 (2007).
- 515 3. Kiando, S.R. *et al.* PHACTR1 Is a Genetic Susceptibility Locus for Fibromuscular
  516 Dysplasia Supporting Its Complex Genetic Pattern of Inheritance. *PLoS Genet* 12, e1006367 (2016).
- 518 4. Gornik, H.L. *et al.* First International Consensus on the diagnosis and management of fibromuscular dysplasia. *Vasc Med* **24**, 164-189 (2019).
- 5. Cordonnier, C. *et al.* Stroke in women from evidence to inequalities. *Nat Rev Neurol* **13**, 521-532 (2017).
- 522 6. Haider, A. *et al.* Sex and gender in cardiovascular medicine: presentation and outcomes of acute coronary syndrome. *Eur Heart J* **41**, 1328-1336 (2020).
- Pappaccogli, M. *et al.* THE EUROPEAN/INTERNATIONAL FIBROMUSCULAR
   DYSPLASIA REGISTRY AND INITIATIVE (FEIRI)- CLINICAL PHENOTYPES
   AND THEIR PREDICTORS BASED ON A COHORT OF ONE THOUSAND
   PATIENTS. *Cardiovasc Res* (2020).
- Plouin, P.F. *et al.* High Prevalence of Multiple Arterial Bed Lesions in Patients With
   Fibromuscular Dysplasia: The ARCADIA Registry (Assessment of Renal and
   Cervical Artery Dysplasia). *Hypertension* **70**, 652-658 (2017).
- 531 9. Olin, J.W. *et al.* The United States Registry for Fibromuscular Dysplasia: results in the
  532 first 447 patients. *Circulation* 125, 3182-90 (2012).
- 533 10. Shivapour, D.M., Erwin, P. & Kim, E. Epidemiology of fibromuscular dysplasia: A
  534 review of the literature. *Vasc Med* 21, 376-81 (2016).
- Hayes, S.N. *et al.* Spontaneous Coronary Artery Dissection: Current State of the
  Science: A Scientific Statement From the American Heart Association. *Circulation*137, e523-e557 (2018).
- 538 12. The Genotype-Tissue Expression (GTEx) project. *Nat Genet* **45**, 580-5 (2013).
- de Leeuw, C.A., Mooij, J.M., Heskes, T. & Posthuma, D. MAGMA: generalized
  gene-set analysis of GWAS data. *PLoS Comput Biol* 11, e1004219 (2015).
- 541 14. Watanabe, K., Taskesen, E., van Bochoven, A. & Posthuma, D. Functional mapping
  542 and annotation of genetic associations with FUMA. *Nat Commun* 8, 1826 (2017).
- 543 15. Gusev, A. *et al.* Integrative approaches for large-scale transcriptome-wide association 544 studies. *Nat Genet* **48**, 245-52 (2016).
- 545 16. Kalluri, A.S. *et al.* Single-Cell Analysis of the Normal Mouse Aorta Reveals
  546 Functionally Distinct Endothelial Cell Populations. *Circulation* 140, 147-163 (2019).
- 547 17. Miller, C.L. *et al.* Integrative functional genomics identifies regulatory mechanisms at coronary artery disease loci. *Nat Commun* 7, 12092 (2016).
- 549 18. Schmidt, E.M. *et al.* GREGOR: evaluating global enrichment of trait-associated
  550 variants in epigenomic features using a systematic, data-driven approach.
  551 *Bioinformatics* 31, 2601-6 (2015).
- 552 19. Evangelou, E. *et al.* Genetic analysis of over 1 million people identifies 535 new loci associated with blood pressure traits. *Nat Genet* 50, 1412-1425 (2018).
- Ni, G., Moser, G., Wray, N.R. & Lee, S.H. Estimation of Genetic Correlation via
  Linkage Disequilibrium Score Regression and Genomic Restricted Maximum
  Likelihood. *Am J Hum Genet* 102, 1185-1194 (2018).

557 558	21.	Hendricks, N.J. <i>et al.</i> Is fibromuscular dysplasia underdiagnosed? A comparison of the prevalence of FMD seen in CORAL trial participants versus a single institution
559		population of renal donor candidates. Vasc Med 19, 363-7 (2014).
560	22.	Giri, A. et al. Trans-ethnic association study of blood pressure determinants in over
561		750,000 individuals. Nat Genet 51, 51-62 (2019).
562	23.	Gormley, P. et al. Meta-analysis of 375,000 individuals identifies 38 susceptibility
563		loci for migraine. Nat Genet 48, 856-66 (2016).
564	24.	Bown, M.J. et al. Abdominal aortic aneurysm is associated with a variant in low-
565		density lipoprotein receptor-related protein 1. Am J Hum Genet 89, 619-27 (2011).
566	25.	Turley, T.N. et al. Identification of Susceptibility Loci for Spontaneous Coronary
567	9.6	Artery Dissection. JAMA Cardiol 5, 1-10 (2020).
568	26.	Saw, J. et al. Chromosome 1q21.2 and additional loci influence risk of spontaneous
569	07	coronary artery dissection and myocardial infarction. <i>Nat Commun</i> <b>11</b> , 4432 (2020).
570	27.	Duan, L. <i>et al.</i> Novel Susceptibility Loci for Moyamoya Disease Revealed by a
571 572	28.	Genome-Wide Association Study. <i>Stroke</i> <b>49</b> , 11-18 (2018). van der Harst, P. & Verweij, N. Identification of 64 Novel Genetic Loci Provides an
572 573	28.	Expanded View on the Genetic Architecture of Coronary Artery Disease. <i>Circ Res</i>
573 574		<b>122</b> , 433-443 (2018).
575	29.	Bres, E.E. & Faissner, A. Low Density Receptor-Related Protein 1 Interactions With
576	27.	the Extracellular Matrix: More Than Meets the Eye. <i>Front Cell Dev Biol</i> <b>7</b> , 31 (2019).
577	30.	Au, D.T. <i>et al.</i> LRP1 (Low-Density Lipoprotein Receptor-Related Protein 1)
578	20.	Regulates Smooth Muscle Contractility by Modulating Ca(2+) Signaling and
579		Expression of Cytoskeleton-Related Proteins. Arterioscler Thromb Vasc Biol 38,
580		2651-2664 (2018).
581	31.	Kobayashi, Y. et al. Mice lacking hypertension candidate gene ATP2B1 in vascular
582		smooth muscle cells show significant blood pressure elevation. Hypertension 59, 854-
583		60 (2012).
584	32.	Okuyama, Y. et al. The effects of anti-hypertensive drugs and the mechanism of
585		hypertension in vascular smooth muscle cell-specific ATP2B1 knockout mice.
586		Hypertens Res 41, 80-87 (2018).
587	33.	Yang, H. et al. NCKX3 was compensated by calcium transporting genes and bone
588		resorption in a NCKX3 KO mouse model. <i>Mol Cell Endocrinol</i> <b>454</b> , 93-102 (2017).
589	34.	Georges, A. et al. Rare Loss-of-function Mutations of PTGIR are enriched in
590	25	Fibromuscular Dysplasia. <i>Cardiovasc Res</i> (2020).
591	35.	Bruno, R.M. <i>et al.</i> Deep Vascular Phenotyping in Patients With Renal Multifocal
592 593	36.	Fibromuscular Dysplasia. Hypertension <b>73</b> , 371-378 (2019).
595 594	30.	Stanley, J.C., Gewertz, B.L., Bove, E.L., Sottiurai, V. & Fry, W.J. Arterial fibrodysplasia. Histopathologic character and current etiologic concepts. <i>Arch Surg</i>
594 595		<b>110</b> , 561-6 (1975).
596	37.	Zhang, Y.Y. <i>et al.</i> A LIMA1 variant promotes low plasma LDL cholesterol and
597	57.	decreases intestinal cholesterol absorption. <i>Science</i> <b>360</b> , 1087-1092 (2018).
598	38.	Morgado, M., Cairrão, E., Santos-Silva, A.J. & Verde, I. Cyclic nucleotide-dependent
599		relaxation pathways in vascular smooth muscle. <i>Cell Mol Life Sci</i> <b>69</b> , 247-66 (2012).
600	39.	Gupta, R.M. et al. A Genetic Variant Associated with Five Vascular Diseases Is a
601		Distal Regulator of Endothelin-1 Gene Expression. Cell 170, 522-533.e15 (2017).
602	40.	Adlam, D. et al. Association of the PHACTR1/EDN1 Genetic Locus With
603		Spontaneous Coronary Artery Dissection. J Am Coll Cardiol 73, 58-66 (2019).
604	41.	Wang, X. & Musunuru, K. Confirmation of Causal rs9349379- PHACTR1 Expression
605		Quantitative Trait Locus in Human-Induced Pluripotent Stem Cell Endothelial Cells.
606		<i>Circ Genom Precis Med</i> <b>11</b> , e002327 (2018).

607	42.	Olin, J.W. et al. A Plasma Proteogenomic Signature for Fibromuscular Dysplasia.
608		Cardiovasc Res (2019).
609 610	43.	Wiezlak, M. <i>et al.</i> G-actin regulates the shuttling and PP1 binding of the RPEL protein Phactr1 to control actomyosin assembly. <i>J Cell Sci</i> <b>125</b> , 5860-72 (2012).
	4.4	
611 612	44.	Beevers, G., Lip, G.Y. & O'Brien, E. ABC of hypertension: The pathophysiology of hypertension. <i>Bmj</i> <b>322</b> , 912-6 (2001).
613	45.	Etminan, N. <i>et al.</i> Worldwide Incidence of Aneurysmal Subarachnoid Hemorrhage
614	ч.).	According to Region, Time Period, Blood Pressure, and Smoking Prevalence in the
615		Population: A Systematic Review and Meta-analysis. JAMA Neurol 76, 588-597
616		(2019).
617	46.	Perez-Lopez, F.R., Larrad-Mur, L., Kallen, A., Chedraui, P. & Taylor, H.S. Gender
618		differences in cardiovascular disease: hormonal and biochemical influences. Reprod
619		<i>Sci</i> <b>17</b> , 511-31 (2010).
620	47.	Vascular factors and risk of dementia: design of the Three-City Study and baseline
621		characteristics of the study population. <i>Neuroepidemiology</i> <b>22</b> , 316-25 (2003).
622	48.	Ye, Z., Kalloo, F.S., Dalenberg, A.K. & Kullo, I.J. An electronic medical record-
623		linked biorepository to identify novel biomarkers for atherosclerotic cardiovascular
624		disease. Glob Cardiol Sci Pract <b>2013</b> , 82-90 (2013).
625	49.	Dobrowolski, P. et al. Echocardiographic assessment of left ventricular morphology
626		and function in patients with fibromuscular dysplasia: the ARCADIA-POL study. J
627		Hypertens <b>36</b> , 1318-1325 (2018).
628	50.	Drygas, W. <i>et al.</i> Multi-centre National Population Health Examination Survey
629		(WOBASZ II study): assumptions, methods, and implementation. <i>Kardiol Pol</i> 74,
630		681-90 (2016).
631	51.	Fritsche, L.G. et al. Association of Polygenic Risk Scores for Multiple Cancers in a
632		Phenome-wide Study: Results from The Michigan Genomics Initiative. Am J Hum
633		Genet 102, 1048-1061 (2018).
634	52.	Rietzschel, E.R. et al. Rationale, design, methods and baseline characteristics of the
635		Asklepios Study. Eur J Cardiovasc Prev Rehabil 14, 179-91 (2007).
636	53.	Loh, P.R. et al. Reference-based phasing using the Haplotype Reference Consortium
637		panel. Nat Genet 48, 1443-1448 (2016).
638	54.	Das, S. et al. Next-generation genotype imputation service and methods. Nat Genet
639		<b>48</b> , 1284-1287 (2016).
640	55.	Chang, C.C. et al. Second-generation PLINK: rising to the challenge of larger and
641		richer datasets. Gigascience 4, 7 (2015).
642	56.	Willer, C.J., Li, Y. & Abecasis, G.R. METAL: fast and efficient meta-analysis of
643		genomewide association scans. <i>Bioinformatics</i> <b>26</b> , 2190-1 (2010).
644	57.	Battle, A., Brown, C.D., Engelhardt, B.E. & Montgomery, S.B. Genetic effects on
645		gene expression across human tissues. Nature 550, 204-213 (2017).
646	58.	Liu, B., Gloudemans, M.J., Rao, A.S., Ingelsson, E. & Montgomery, S.B. Abundant
647		associations with gene expression complicate GWAS follow-up. Nat Genet 51, 768-
648		769 (2019).
649	59.	Giambartolomei, C. et al. Bayesian test for colocalisation between pairs of genetic
650		association studies using summary statistics. <i>PLoS Genet</i> <b>10</b> , e1004383 (2014).
651	60.	Corces, M.R. et al. An improved ATAC-seq protocol reduces background and enables
652		interrogation of frozen tissues. Nat Methods 14, 959-962 (2017).
653	61.	Freese, N.H., Norris, D.C. & Loraine, A.E. Integrated genome browser: visual
654		analytics platform for genomics. Bioinformatics 32, 2089-95 (2016).

655	62.	Buniello, A. et al. The NHGRI-EBI GWAS Catalog of published genome-wide
656		association studies, targeted arrays and summary statistics 2019. Nucleic Acids Res 47,
657		D1005-d1012 (2019).
658	63.	Debette, S. et al. Common variation in PHACTR1 is associated with susceptibility to
659		cervical artery dissection. Nat Genet 47, 78-83 (2015).
660	64.	Malik, R. et al. Multiancestry genome-wide association study of 520,000 subjects
661		identifies 32 loci associated with stroke and stroke subtypes. Nat Genet 50, 524-537
662		(2018).
663	65.	Bulik-Sullivan, B.K. et al. LD Score regression distinguishes confounding from
664		polygenicity in genome-wide association studies. Nat Genet 47, 291-5 (2015).
665	66.	Zhu, Z. et al. Causal associations between risk factors and common diseases inferred
666		from GWAS summary data. Nat Commun 9, 224 (2018).
667		

667

#### 668 Ethical Statement

669 All studies involved individual written informed consent from all participants and received 670 approval from respective local ethics committee. The ARCADIA study was approved by the 671 « Comité de Protection des Personnes » CPP Ile-de-France II- ID RCB: 2009-A00288-49. 672 The 3 cities protocol was approved by "comité consultatif de protection des personnes dans la 673 recherche biomédicale Bicêtre Hôpital Bicêtre n°99-28 CCPPRB approved 10/06/99, 674 11/03/2003 and 17/03/2006. ARCADIA-Pol study was approved by Local Ethics Committee, 675 Institute of Cardiology, IK-NPIA-0021017/1482/17. The WOBASZ II Project was accepted 676 by the Field Bioethics Committee of the Institute of Cardiology in Warsaw (IK-NP-0021-677 69/1344/12). All centres included in FEIRI received approval from the respective local/ 678 national ethics committees. ASKLEPIOS study was approved by the ethical committee of the 679 Ghent University Hospital, Belgium. The DEFINE case control study is a Mount Sinai 680 Health System Study ID: HSM# 13-00575 / GCO# 13-1118. The Mayo Clinic case control 681 study was approved by Mayo Clinic IRB #08-008355. The UM case control study was 682 approved by University of Michigan IRB #HUM00044507, #HUM00112101 and Cleveland 683 Clinic IRB approval #10-318

- 684
- 685

It is made available under a CC-BY-NC-ND 4.0 International license .

#### 686 Acknowledgements

687 We thank all patients who participated in these studies. We thank Dr Antoine Chédid for 688 collecting and managing clinical data of patients in ARCADIA protocol. We thank Patrick 689 Bruneval for his scientific input and exchanges about arterial pathology in FMD. This study 690 contributes to the IdEx Université de Paris ANR-18-IDEX-0001. This work has benefited 691 from the facilities and expertise of the high throughput sequencing core facility of I2BC 692 (Centre de Recherche de Gif - http://www.i2bc.paris-saclay.fr/). ARCADIA-Pol investigators 693 thank Ewa Rudolf, Elzbieta Pazio and Małgorzata Lewandowska, who were responsible for 694 all administrative work. The Steering Committee of the WOBASZ study expresses special 695 thanks for participation in the implementation of the study to: all their co-workers from 696 research teams at six academic centres, to nurses, doctors, and analysts from field research 697 centres located in 16 voivodeships. We acknowledge the Spanish National Cancer Research 698 Centre (CNIO), in the Human Genotyping lab, a member of CeGen where genotyping was 699 performed for part of the cohorts studied. We thank the participants of the study and the 700 Fibromuscular Dysplasia Society of America for facilitating the enrolment of subjects at their 701 annual meetings. We thank the Frankel Cardiovascular Center and M-BRISC program for 702 their support and the University of Michigan Advanced Genomics Core where MGI study 703 performed genotyping. The authors acknowledge the University of Michigan Precision Health 704 Initiative and Medical School Central Biorepository for providing biospecimen storage, 705 management, processing and distribution services and the Center for Statistical Genetics in 706 the Department of Biostatistics at the School of Public Health for genotype data management 707 in support of this research. Some illustrations were designed by macrovector / Freepik.

708

709

It is made available under a CC-BY-NC-ND 4.0 International license .

#### 711 Funding

712 This study was supported by the European Research Council grant (ERC-Stg-ROSALIND-713 716628) to NB-N and National Institute of Health grant (R01 HL139672) to SKG. The 714 ARCADIA study was sponsored by the Assistance Publique-Hôpitaux de Paris and funded by 715 a grant from the French Ministry of Health (Programme Hospitalier de Recherche Clinique 716 2009, AOM 08192) and the Fondation de Recherche sur l'Hypertension Artérielle. 717 Genotyping of French study was supported by the French research agency (ANR-13-JSV1-718 0002) to NB-N. The genotyping of controls from the Three-City Study (3C) was supported by 719 the non-profit organization Fondation Alzheimer (Paris, France) to PA. ARCADIA-Pol study 720 was supported by the grant no. 2.40/III/19 of Institute of Cardiology, Poland. The WOBASZ 721 II Project was financed from the resources at the disposal of the Polish Minister of Health 722 within the framework of the "National Program of Equalization and Accessibility to 723 Cardiovascular Disease Prevention and Treatment for 2010-2012. MV benefited from Fonds 724 de la Recherche Scientifique - FNRS Grant T.0247.19, Belgium. The Spanish National 725 Cancer Research Centre (CNIO), in the Human Genotyping lab, a member of CeGen 726 Biomolecular resources platform (PRB3), is supported by grant PT17 /0019, of the PE I+D+i 727 2013-2016, funded by Instituto de Salud Carlos III and a European regional development 728 fund (ERDF). DEFINE-FMD is supported by NIH grant 1R01HL148167-01A1 to JCK. BAS 729 is supported by the Mayo Clinic Clinician-Investigator Training Program. IJK is additionally 730 supported by NIH grant K24HL137010. The UM study is supported by NHLBI/NIH (R01 731 HL139672, R01 HL122684), the University of Michigan Taubman Institute, Frankel 732 Cardiovascular Center. S.K.G. is supported by R01HL139672, R01HL122684, and 733 R01HL086694. The Michigan Genomics Initiative was supported by the University of 734 Michigan Precision Health Initiative. The Cleveland Clinic Biorepository was supported by 735 CTSA 1UL1RR024989. The Cleveland Clinic FMD Biorepository has been supported in part

It is made available under a CC-BY-NC-ND 4.0 International license .

736 by the National Institutes of Health, National Center for Research Resources, CTSA 737 1UL1RR024989, Cleveland, Ohio. YR received funding from the European Research Council 738 (ERC) under the European Union's Horizon 2020 research and innovation program (grant 739 agreement No. 852173). Intracranial aneurysm working group acknowledges the support from 740 the Netherlands Cardiovascular Research Initiative: an initiative with support of the Dutch 741 Heart Foundation, CVON2015-08 ERASE. 742 743 **Authors contributions** 744 Writing and editing the manuscript: AG, T-EB, SKG, NB-N. Study design / conception: AG, 745 T-EB, SKG, NB-N. Genotyping experiments: J-FD, DD, KLH, MV. Sample /phenotype 746 contribution: LA, CAB, CMB, DMC, HG, SKG, PDL, NF-M, DK-D, JZL, AL, MP, AP, WS, 747 JCS, MZ, XZ, SZ, FEIRI Consortium, PA, MLdB, SD, PD, WD, HLG, JWO, JP, ERR, EW-748 C, AJ, IJK, MA, XJ, AP, JCK. GWAS analyses: M-LY, T-EB, MB, OD, SRK, LM, BAS, SS, 749 MY, XZ, JZL. Gene-based and LD score analyses: T-EB. Functional annotation experiments: 750 AG, SK, LL. TWAS, in silico functional annotations: AG. eQTL colocalization analyses: M-751 LY. Data for IA/SAH genetic correlation: MB, ISGC intracranial working group, YR. Data

752 for stroke genetic correlation: MEGASTROKE. eQTL data and analysis in FMD and control

753 fibroblasts: LM, Vd'E, JCK.

754

#### 755 **Competing Interest**

HLG, SKG, JO, and JCS are non-compensated members of the Medical Advisory Board of
the FMD Society of America (FMDSA). SKG is a non-compensated member of the Scientific
Advisory Board of SCAD Alliance. Both are non-profit organizations.

759

It is made available under a CC-BY-NC-ND 4.0 International license .

#### 761 **Data availability**

- 762 Data will be made available after acceptance of the article.
- 763

#### 764 **Figure legends**

#### 765 Figure 1. SNP-based, gene-based and transcriptome wide association analyses

766 **a:** Manhattan plot representation of SNP-based association analysis in multifocal FMD.  $-\log_{10}$ 767 of association *P*-value is represented on the y-axis, genomic coordinates on the x-axis. Name of lead SNPs with *P*-value  $\leq 5 \times 10^{-8}$  are indicated. **b-c:** Manhattan plot representation of **b**: 768 769 gene-based association analysis in multifocal FMD; c: Transcriptome-wide association 770 analysis (TWAS) in FMD with tibial artery gene expression models. -log<sub>10</sub> of association P-771 value is represented on the y-axis, genomic coordinates on the x-axis. Name of genes with 772 Bonferroni corrected *P*-value  $\leq 0.05$  are indicated. **d**: Volcano plot representation of FMD 773 TWAS. TWAS Z-score is represented on the x-axis,  $-\log_{10}$  of TWAS *P*-value on the y-axis. 774 Dashed line represents the threshold for significance adjusted for multiple testing. Name of 775 genes with Bonferroni adjusted P-value < 0.05 are indicated.

776

#### 777 Figure 2. Tissue-wide eQTL signals near FMD loci

778 a: Heatmap representation of eQTL signals at FMD loci. GTEx v8 database was queried for 779 significant eQTLs using the lead variant rsID number. All genes identified as positive eQTL 780 in at least one tissue were selected to calculate eQTL associations in all tissues available in 781 this database. The negative logarithm  $(-\log_{10})$  of the eQTL association *P*-values are 782 represented in a blue-red colour scale. b, d, f, h: Violin plots representing normalized 783 expression of PHACTR1 (b), LRP1 (d), ATP2B1 (f) and ATF1 (h) by genotype of lead SNPs 784 in tibial artery (**b**, **d**, **f**) and aortic tissue (**h**). Plots illustrate the best eQTL association in 785 arterial tissue for the lead SNP at each locus. eQTL P-value is indicated. c, e, g, i:

It is made available under a CC-BY-NC-ND 4.0 International license .

Colocalization plot of FMD association (x-axis, log scale of *P*-value) with arterial eQTL association (y-axis, log-scale of *P*-value) at each locus. Dot colour represents the LD  $r^2$  with the lead variant in 1000G European samples. FMD lead variant is highlighted (Diamond shape, purple). Approximate Bayes Factor Posterior Probability (*PP.abf*) for the two traits to share a common causal variant is indicated.

791

#### 792 Figure 3. Characterization of open chromatin regions in artery derived primary cells

793 **a**: Number of reads (grey) and number of peaks (orange) obtained for ATAC-Seq libraries 794 from primary cells and artery tissue. HCtASMC: human carotid artery smooth muscle cells, 795 HCASMC: human coronary artery smooth muscle cells, HCtAEC: human carotid artery 796 endothelial cells, HCAEC: human coronary artery endothelial cells, HDF: human dermal 797 fibroblasts, HCF: human cardiac fibroblasts, NCA: normal coronary arteries. NCA ATAC-Seq libraries were generated and sequenced by Miller and colleagues<sup>17</sup> and raw reads were 798 799 retrieved from the sequence read archive (https://www.ncbi.nlm.nih.gov/sra). b: Heatmap 800 representation of Spearman correlation and hierarchical clustering of ATAC-Seq datasets. 801 The three main clusters correspond to VSMCs/fibroblasts, ECs and arteries, and are identified 802 on the dendrogram. Rho correlation coefficient is represented by a red-blue colour scale and 803 indicated in each box. c: Principal component analysis of ATAC-Seq datasets. Upper panel 804 shows the position of samples with respect to first two principal components. Lower panel 805 indicates the eigenvalues of the first 10 principal components. d: Representation of FMD 806 SNPs fold-enrichment (x-axis) and enrichment P-value (log scale, y-axis) among indicated ATAC-Seq samples. The overlap of FMD lead SNPs ( $P < 10^{-4}$  for the lead SNP) and proxies 807 808  $(r^2 \ge 0.7)$  with ATAC-Seq peaks was compared to 500 pools of randomized matched SNPs to 809 calculate the indicated enrichments. Lower panel shows the average fold enrichment in each group of samples. e: Bubble graph representing the clustering of enriched ( $P < 10^{-3}$ ) gene 810

It is made available under a CC-BY-NC-ND 4.0 International license .

811 ontology (GO) Biological Processes terms among genes (N=1425) located in the vicinity of 812 artery-specific open chromatin regions (regions enriched over VSMCs and ECs). Similar 813 terms were grouped using REVIGO webserver (http://revigo.irb.hr/) with "Medium" setting. 814 Bubble size indicates the number of enriched GO terms in each group. Bubble colour 815 indicates the P-value of the most enriched term in each group. X- and Y-axes represent 816 arbitrary semantic coordinates. f: Bar plot representing the enrichment score of the top 5 817 clusters obtained by Functional Annotation Clustering of the indicated 1425 genes using 818 DAVID webserver (https://david.ncifcrf.gov/home.jsp). Most enriched term is indicated for 819 each cluster.

820

#### 821 Figure 4. Visualization of potential causal variants genes at FMD-associated loci

822 **a, c, e, g**: LocusZoom representation of FMD associated loci (**a**: *PHACTR1* locus, **c**: *LRP1* 

823 locus, e: ATP2B1 locus, g: LIMA1 locus). Dot colour indicates LD of each variant with the

824 highlighted lead variant (purple diamond). Position and rsID of putative causal variants are

825 indicated. **b**, **d**, **f**, **h**: Genome browser visualization of ATAC-Seq/Histone ChIP read densities

826 (in reads/million, r.p.m.) in the regions surrounding putative causal variants. b: PHACTR1

827 locus. **d**: *LRP1* locus. **f**: *ATP2B1* locus. **h**: *LIMA1* locus. Grey line highlights variant position.

828

#### 829 Figure 5. Pairwise trait colocalization of FMD associations

830 **a**: Associations of FMD loci with other vascular diseases. Variants in LD ( $r^2 > 0.5$ ) with the 831 lead SNP were used to query GWAS catalog database (accessed on August 5<sup>th</sup> 2020), UK 832 BioBank GWAS traits and specific meta-analysis of GWAS for CAD/MI, stroke, blood 833 pressure and intracranial aneurysms. Two independent lead SNPs were retained for *SLC24A3* 834 locus. Overlaps are reported for the following traits/diseases: hypertension (HTN), pulse 835 pressure (PP), systolic blood pressure (SBP), diastolic blood pressure (DBP), migraine (Mig),

It is made available under a CC-BY-NC-ND 4.0 International license .

836 cervical artery dissection (CeAD), spontaneous coronary artery dissection (SCAD), 837 abdominal aortic aneurysm (AAA), MoyaMoya disease (MD), coronary artery calcification 838 (CAC), coronary artery disease (CAD) and myocardial infarction (MI). Large bubbles indicate association below genome-wide significance for the corresponding trait ( $P < 5 \times 10^{-8}$ ), 839 smaller bubbles correspond to suggestive signals ( $P < 1 \times 10^{-5}$ ). Red colour indicates same 840 841 direction effects of risk alleles compared to the association with FMD, blue colour opposite 842 direction associations. b: Heatmap representation of TWAS Z-Score for FMD associated 843 genes. TWAS was performed with tibial artery gene expression models for the indicated traits 844 or diseases (x-axis). Z-scores are shown for all FMD associated genes in the gene-based and 845 TWAS analyses (y-axis).

846

#### 847 Figure 6. Genetic correlations between FMD and other traits and diseases

848 a: Genetic correlation obtained using LD Score analyses between FMD and vascular diseases 849 and traits. HTN: hypertension, CAD: coronary artery disease, MI: myocardial infarction, AS: 850 any stroke, AIS: any ischemic stroke, LAS: large artery stroke, CES: cardioembolic stroke, 851 SVS: small vessel stroke, IA: intracranial aneurysm, all forms, SAH: aneurysmal 852 subarachnoid haemorrhage, i.e. ruptured intracranial aneurysm, uIA: unruptured intracranial 853 aneurysm. b: Genetic correlation obtained using LD Score analyses between FMD and 854 vascular diseases and metabolic traits. HDL: high density lipoprotein, LDL: low density 855 lipoprotein, TC: total cholesterol, TG: triglycerides, ApoA: apolipoprotein A, ApoB: 856 apolipoprotein B, eGFR: estimated glomerular filtration rate (calculated with creatinine or 857 cystatin), UACR: urine albumin to creatinine ratio, BUN: blood urea nitrogen, CRP: C-858 reactive protein. c, d: Genetic correlation results after FMD genetic association statistics was 859 conditioned on systolic blood pressure. \*: P-value is below the multiple testing threshold for 860 significance  $(1.6 \times 10^{-3} \text{ for } 31 \text{ tests})$ .

It is made available under a CC-BY-NC-ND 4.0 International license .

#### 861 **METHODS**

#### 862 Patients and control populations

The meta-analysis included participants of European ancestry from six studies: ARCADIA<sup>8</sup>/3C<sup>47</sup> GWAS, Mayo Vascular Disease Biorepository<sup>48</sup>, DEFINE-FMD study<sup>42</sup>, ARCADIA-POL<sup>49</sup>/WOBASZII<sup>50</sup> study, University of Michigan/Cleveland Clinic (UM) study<sup>26,51</sup> and FEIRI<sup>7</sup>/ASKLEPIOS<sup>52</sup> study. FMD patients presented similar clinical characteristics (**Supplementary Table S1**) and homogeneous diagnosis, exclusion and inclusion criteria. Detailed description of the participating cohorts is available in the supplementary appendix.

870

#### 871 Genome-wide association analyses and meta-analysis

872 Details on genotyping, variant calling for each cohort and pre-imputation quality control in each study are listed in Supplementary Table S12. In brief, genotyping was performed using 873 874 commercially available arrays. To increase the number of tested SNPs and the overlap of 875 variants available for analysis between different arrays, all European ancestry cohorts imputed genotypes to the most current HRC v1.1 reference panel<sup>53</sup> on the Michigan Imputation 876 Server<sup>54</sup>. GWAS was conducted in each study under an additive genetic model using PLINK 877  $v2.0^{55}$ . Models were adjusted for population structure using the first five principal 878 879 components, sex (except in the women-only analyses) and study specific genomic control. 880 Prior to meta-analysis, we removed single nucleotide polymorphisms (SNPs) with low minor allele frequencies (MAF) ( $< \Box 0.01$ ), low imputation quality ( $r^2 < 0.8$  for French and UM 881 studies and  $r^2 < \Box 0.3$  for the others studies), and deviations from Hardy-Weinberg equilibrium 882  $(P \square < \square 10^{-\square 5})$ . A total of 6,477,066 variants met these criteria and were kept in the final 883 884 results.

It is made available under a CC-BY-NC-ND 4.0 International license .

Association results were combined using an inverse variance weighted fixed-effects metaanalysis in METAL software<sup>56</sup>, with correction for genomic control. Heterogeneity was assessed using the I<sup>2</sup> metric from the complete study-level meta-analysis. Between-study heterogeneity was tested using the Cochran Q statistic and considered significant at  $P \cong \le 10^{-18}$ . <sup>3</sup> Genome-wide significance threshold was set at the level of  $P \cong = 5.0 \square \times \square 10^{-\square 8}$ . LocusZoom (http://locuszoom.org/) was used to provide regional visualization of results.

#### 891 eQTL and colocalization analyses

We queried GTEx database (v8 release)<sup>57</sup> with rsID of lead variants at FMD loci in arterial 892 893 tissues for major associated genes (permutations q-value<0.05). For each identified gene, 894 variant-gene association was queried in all tissues using "eQTL calculator" function on GTEx 895 website (https://gtexportal.org/home/). Uncharacterized non-coding transcripts were excluded 896 from the analysis. For colocalization, three arterial samples (aorta, coronary, tibial) from 897 GTEx were pooled at each locus to compare with the FMD GWAS meta-analysis result and 898 the multifocal FMD GWAS meta-analysis result. We generated colocalization plots using 899 locuscompareR package<sup>58</sup> and Bayesian posterior probability was calculated using coloc.abf function in R coloc package<sup>59</sup>. The eOTL association results from coronary, tibial and aorta 900 901 arterial tissues were all retrieved for each transcript at each locus for Bayesian posterior 902 probability analysis, and the minimal P-values across these three tissues for each locus were 903 taken for generating the colocalization plots.

904

#### 905 Gene-based and transcriptome-wide association analyses

Gene based association was conducted using the MAGMA tool<sup>13</sup>, implemented in the FUMA
platform<sup>14</sup>. Locations of protein-coding genes were defined as the regions from transcription
start site to transcription stop site (default option in MAGMA). TWAS was performed using
FUSION R/python package<sup>15</sup>. Gene expression models were precomputed from GTEx data

It is made available under a CC-BY-NC-ND 4.0 International license .

910 (v7 release) and were provided by the authors. Only genes with heritability *P*-value < 0.01911 were used in the analysis. Uncharacterized non-coding transcripts were excluded from the 912 analysis. Both tools used linkage disequilibrium information from the European panel of the 913 1000 Genomes phase 3. Bonferroni multiple testing correction was applied using the p.adjust 914 function in R (v 3.6.1).

915

#### 916 Primary cell culture and ATAC-Seq experiments

917 With the exception of the dermal fibroblast cell lines obtained under the DEFINE-FMD 918 protocol, other primary cells were purchased from Cell Applications (San Diego, CA) except 919 HDF (ATCC, Manassas, VA) and cultured with 5% CO2 in a 37°C incubator following 920 manufacturer's instructions. VSMC cells were grown in DMEM supplemented with 5% FBS, 921 Insulin (5µg/mL), EGF (0.5ng/mL), bFGF (2ng/mL) and antibiotics. Cells were at passage 5 922 (HDF, HCF, HCtAEC, HCAEC) or 6 (HCtASMC, HCASMC) for ATAC-Seq analyses. 923 ATAC-Seq was performed following the Omni-ATAC protocol described previously<sup>60</sup>. 924 Detailed description of ATAC-Seq experiments and analyses is in the supplementary 925 appendix.

926

#### 927 Annotation with epigenomic data

We computed the overlap of variant with open chromatin regions (narrowpeak from MACS2 output + 100bp on each side) and histone-ChIP peaks using bedtools (v2.29.0) annotate function. Full list of peak files used is available in **Supplementary Table S13**. Analysis of SNP enrichment among ATAC-Seq peaks was performed using GREGOR<sup>18</sup>. The lead SNPs from loci associated with *P*-value <  $10^{-4}$  were used as reference for FMD-associated SNPs. We included in the analysis SNPs in LD with lead SNPs ( $r^2 \ge 0.7$  in the European subset of the

It is made available under a CC-BY-NC-ND 4.0 International license .

- 934 1000 Genomes phase 3 reference panel). We used Integrated Genome Browser (IGB, v9.1.4)
- 935 to visualize read density profiles and peak positions in the context of human genome $^{61}$ .
- 936

#### 937 Overlap between FMD loci and other traits and diseases

We queried the GWAS catalog database<sup>62</sup>, UK Biobank GWAS summary statistics made 938 939 publicly available by the Neale lab at the Broad Institute (http://www.nealelab.is/uk-biobank) 940 and GWAS meta-analyses on blood pressure<sup>19</sup>, spontaneous coronary artery dissection<sup>25</sup>, cervical artery dissection<sup>63</sup>, CAD/MI<sup>28</sup>, IA/uIA/SAH (Bakker et al., Nature Genetics, in press, 941 pre-publication access) and Stroke<sup>64</sup> with FMD lead SNPs and LD proxies ( $r^2 \ge 0.5$  in the 942 943 European panel of the 1000 Genomes phase 3). We reported vascular phenotypes with at least one variant with genome-wide ( $P < 5 \times 10^{-8}$ ) or suggestive ( $P < 10^{-5}$ ) association. Colocalization 944 plots were generated using locuscompareR package<sup>58</sup>. Comparative TWAS in FMD and other 945 946 traits was performed using HapMap filtered summary statistics (see below).

947

#### 948 Genetic correlation analyses

949 We used LD score regression to estimate the genetic correlation between FMD and other 950 diseases and traits<sup>65</sup>. Summary statistics were acquired from the respective consortia and are 951 detailed in **Supplementary Table S14.** For each trait, we filtered the summary statistics to 952 the subset of HapMap 3 SNPs to decrease the potential for bias due to poor imputation 953 quality. Correlation analyses were restricted to summary statistics from European ancestry 954 meta-analyses. We used the European LD-score files calculated from the 1000G reference panel and provided by the developers. A  $P < 1.6 \times 10^{-3}$ , corresponding to adjustement for 31 955 956 independent phenotypes was considered significant. All analyses were performed with the 957 ldsc package (v1.0.1, https://github.com/bulik/ldsc/). We conditioned FMD association on 958 systolic blood pressure genetic association using multi-trait-based conditional and joint

It is made available under a CC-BY-NC-ND 4.0 International license .

- analysis (mtCOJO) tool from GCTA pipeline<sup>66</sup>. The resulting summary statistics were then
- 960 used to calculate genetic correlation between FMD, conditioned on systolic blood pressure,
- and the previous traits.

#### 962 Table 1: FMD associated variants in SNP association analyses

963

Meta-analysis was performed using inverse variance-weighted method. Heterogeneity between cohorts was tested using Cochran's Q statistics
 and was not significant. Chr: chromosome, EA: effect allele, EAF: effect allele frequency, OR: odds ratio

966

967

		Lead Var	iant			All FM 1962 ca 7100 con	ses	Multifoca 1578 c 7100 co	ases	Women FMD 1715 cases 5724 controls		
rsID	Chr	Position (hg19)	EA	EAF	Locus	OR (95% CI)	<i>P</i> -value	OR (95% CI)	<i>P</i> -value		P-value	
rs9349379	6	12903957	А	0.63	PHACTR1	1.39 (1.28 - 1.51)	2.0×10 <sup>-14</sup>	1.44 (1.31 - 1.57)	5.2×10 <sup>-15</sup>	1.43 (1.30 - 1.56)	1.3×10 <sup>-14</sup>	
rs11172113	12	57527283	Т	0.62	LRP1	1.31 (1.20 - 1.43)	2.6×10 <sup>-10</sup>	1.34 (1.22 - 1.46)	2.0×10 <sup>-10</sup>	1.32 (1.20 - 1.44)	1.5×10 <sup>-9</sup>	
rs17249754	12	90060586	G	0.84	ATP2B1	1.41 (1.26 - 1.58)	5.9×10 <sup>-9</sup>	1.43 (1.26 - 1.62)	1.7×10 <sup>-8</sup>	1.44 (1.27 - 1.63)	8.1×10 <sup>-9</sup>	
rs6580732	12	50646279	Т	0.45	LIMA1	1.24 (1.14 - 1.34)	1.4×10 <sup>-7</sup>	1.30 (1.19 - 1.41)	2.2×10 <sup>-9</sup>	1.29 (1.18 - 1.40)	7.4×10 <sup>-9</sup>	

It is made available under a CC-BY-NC-ND 4.0 International license

#### 968 Table 2. FMD associated genes in gene-based and transcriptome-wide association analyses

969 The table shows *P*-values (*P*) of gene-based association calculated with MAGMA, uncorrected and corrected for multiple testing, and p-values

970 and Z-scores (Z) of trancriptome-wide association based on gene-expression models from GTEx in tibial artery and GWAS in all FMD. All

971 genes with Bonferroni corrected *P*-value below 0.05 in at least one condition are reported and the condition where the gene association reaches

972 adjusted significance are highlighted in bold. Lead SNP is the one with the lowest *P*-value in GWAS in all FMD.

973 Best *P*: lowest *P*-value of the lead SNP in the three GWAS (all FMD cases, multifocal FMD or women) Chr: Chromosome, Bonf. : Bonferroni 974 corrected *P*-value, N/A: not available

975

Locus information			Gene	e information			TWAS						
						Al	1	Multi	focal	Won	nen	Tibial Arteries	
Lead SNP	Best P	Gene	Chr	Start (hg19)	Stop (hg19)	Р	Bonf.	Р	Bonf.	Р	Bonf.	Р	Z
rs9349379	5.2×10 <sup>-15</sup>	PHACTR1	6	12717893	13288645	1.7×10 <sup>-4</sup>	1.00	5.6×10 <sup>-5</sup>	1.00	1.5×10 <sup>-4</sup>	1.00	1.1×10 <sup>-11</sup>	6.8
rs11172113	2.0×10 <sup>-10</sup>	LRP1	12	57522276	57607134	2.5×10 <sup>-3</sup>	1.00	2.5×10 <sup>-3</sup>	1.00	4.1×10 <sup>-3</sup>	1.00	2.7×10 <sup>-10</sup>	6.3
1311172113	2.0~10	STAT6	12	57489260	57525922	3.7×10 <sup>-6</sup>	0.07	2.4×10 <sup>-6</sup>	0.04	2.0×10 <sup>-5</sup>	0.38	8.3×10 <sup>-2</sup>	-1.7
rs17249754	5.9×10 <sup>-9</sup>	ATP2B1	12	89981828	90102608	3.8×10 <sup>-5</sup>	0.70	7.4×10 <sup>-5</sup>	1.00	7.9×10 <sup>-5</sup>	1.00	3.7×10 <sup>-6</sup>	-4.6
		LIMA1	12	50569571	50677329	2.4×10 <sup>-6</sup>	0.04	5.7×10 <sup>-7</sup>	0.01	3.0×10 <sup>-7</sup>	0.01	7.0×10 <sup>-3</sup>	2.7
rs6580732	2.2×10 <sup>-9</sup>	ATF1	12	51157493	51214905	7.7×10 <sup>-6</sup>	0.14	7.3×10 <sup>-7</sup>	0.01	1.5×10 <sup>-6</sup>	0.03	2.0×10 <sup>-3</sup>	-3.1
		GPD1	12	50497602	50505102	2.8×10 <sup>-6</sup>	0.05	7.3×10 <sup>-7</sup>	0.01	8.2×10 <sup>-7</sup>	0.02	N/A	N/A
rs2424245	4.0×10 <sup>-7</sup>	SLC24A3	20	19193290	19703581	4.5×10 <sup>-6</sup>	0.08	4.7×10 <sup>-4</sup>	1.00	4.8×10 <sup>-5</sup>	0.89	5.1×10 <sup>-9</sup>	-5.8

#### 977 Table 3. Candidate causal variants at FMD associated loci

978 All variants with at least suggestive association ( $P < 5 \times 10^{-6}$ ) in the global FMD association studies and in high LD ( $r^2 \ge 0.5$ ) with the lead SNP of each locus were tested for

979 overlap with open chromatin regions in coronary artery tissue, carotid/coronary artery derived primary cells, dermal fibroblasts and histone marks in artery tissues (aorta, coronary or tibial arteries) from ENCODE databases. N SNPs indicate the number of SNPs tested at each locus. Best P indicates the lowest *P*-value of the SNP in the three

981 GWAS (all FMD cases, multifocal FMD or women FMD). Grey colour indicates overlap of the variant with at least one dataset of the corresponding category. \*: Variant with

982 genome-wide significant association with FMD.

		ATAC-Seq										Histone ChIP-Seq			
Locus		SNP information						Coronary Carotid			Dermal	A			
						Artery			Artery		Fibroblasts	Any arteries			
Lead SNP	Ν	SNP	Chr	Pos	LD	Best P	Whole	SMC	EC	SMC	EC	HDF	H3K4me1	H3K4me3	H3K27ac
	SNPs	0112	0	(hg38)	$(hg38)$ $(r^2)$	20001	Tissue	51120	20	520	20				110112/40
rs9349379	1	rs9349379*	6	1290372	1.00	$5.2 \times 10^{-15}$									-
rs11172113	3	rs4759275	12	5713197	0.76	$2.9 \times 10^{-6}$									
		rs11172113*	12	5713350	1.00	2.0×10 <sup>-10</sup>									
		rs11105352*	12	8963268	1.00	$8.0 \times 10^{-9}$									
rs17249754	30	rs11105353*	12	8963268	1.00	$8.0 \times 10^{-9}$									
1817249734	50	rs11105354*	12	8963274	1.00	6.8×10 <sup>-9</sup>									
		rs73437382	12	8970916	0.50	$1.4 \times 10^{-6}$									
		rs2280715	12	8970992	0.51	1.8×10 <sup>-6</sup>								_	
		rs7967705	12	5011762	0.72	2.6×10 <sup>-7</sup>									
		rs7297421	12	5012514		$4.0 \times 10^{-7}$									
		rs7308356	12	5014582	0.73	4.3×10 <sup>-7</sup>									
		rs12815871	12	5015716	0.72	$1.7 \times 10^{-7}$									
		rs7301566*	12			$1.3 \times 10^{-9}$									
		rs2358538	12	5019284	0.83	$8.9 \times 10^{-8}$									
rs6580732	117	rs4459386* rs1862042	12 12	5020116 5021144	$1.00 \\ 0.87$	2.9×10 <sup>-9</sup> 4.2×10 <sup>-7</sup>						_			
150500752	117	rs10783342*	12	5023468	1.00	$4.2 \times 10^{-9}$ $6.8 \times 10^{-9}$									
		rs7309519	12	5025849	0.87	$9.7 \times 10^{-8}$									
		rs10747586	12	5058978	0.67	8.2×10 <sup>-7</sup>									
		rs7305655	12	5061150	0.67	8.7×10 <sup>-7</sup>									
		rs2700479	12	5062668	0.67	$4.2 \times 10^{-7}$									
		rs2684889	12	5062600	0.67	3.1×10 <sup>-7</sup>									
		rs1109726	12			$1.1 \times 10^{-6}$									

It is made available under a CC-BY-NC-ND 4.0 International license









а





